The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

Mon, 18th Dec 2023 16:55

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

The FTSE 100 index closed up 38.12 points, 0.5%, at 7,614.48. The FTSE 250 ended up 11.58 points, 0.1%, at 19,220.55, and the AIM All-Share closed up 1.88 points, or 0.3%, at 741.19.

The Cboe UK 100 ended up 0.5% at 760.32, the Cboe UK 250 closed up 0.1% at 16,679.25, and the Cboe Small Companies ended up 0.5% at 14,370.59.

In European equities on Monday, the CAC 40 in Paris ended down 0.4%, while the DAX 40 in Frankfurt ended down 0.6%.

On Monday, markets were digesting some hawkish comments from US Federal Reserve officials.

This is a move away from Wednesday's pivot, when the Fed left US interest rates unchanged, but signalled for cuts in 2024.

New York Federal Reserve President John Williams told CNBC's 'Squawk Box' that the central bank isn't "really talking about rate cuts right now".

Separately, Atlanta Fed President Raphael Bostic, who votes on monetary policy next year, told Reuters that he expects two rate cuts in 2024 but not starting until the third quarter. Meanwhile, Loretta Mester, the president of Cleveland Fed, said markets are a "bit ahead" of central bank on rate cuts.

AJ Bell's Russ Mould said the comments has left markets "somewhat in limbo."

Still to come this week, there are US gross domestic product readings, as well as core inflation figures. The data could give investors more guidance about where interest rates might go.

Stocks in New York were higher at the London equities close, with the DJIA up 0.2%, the S&P 500 index up 0.5%, and the Nasdaq Composite up 0.4%.

The pound was quoted at USD1.2640 at the London equities close Monday, lower compared to USD1.2693 at the close on Friday. The euro stood at USD1.0914 at the European equities close Monday, slightly higher against USD1.0912 at the same time on Friday.

We still aren't done with interest rates decision for 2023. The Bank of Japan announces its monetary policy on Tuesday.

According to a Bloomberg report last Monday citing "people familiar with the matter", the BoJ is likely to keep its ultra-loose monetary policy in place, despite recent market speculation that the negative rate may be scrapped.

Against the yen, the dollar was trading at JPY143.05, higher compared to JPY141.75 late Friday.

In the FTSE 100, BP rose 1.6%.

The oil firm said it had joined other companies in suspending transits through the Red Sea, after Yemen's Huthi rebels targeted Israel with missiles.

"In light of the deteriorating security situation for shipping in the Red Sea, BP has decided to temporarily pause all transits," a statement said.

"We will keep this precautionary pause under ongoing review, subject to circumstances as they evolve in the region," it added.

SPI Asset Management's Stephen Innes explained: "It appears that a cohort of traders are taking hedging precautions against the tail risk associated with the Strait of Hormuz, which is providing the bid today. The Houthis' focus on vessels with ties to Israeli ownership or those engaged in shipping cargo to Israel through the Red Sea has raised concerns."

Peer Shell rose 1.4%.

Brent oil was quoted at USD78.52 a barrel at the London equities close Monday, up from USD76.34 late Friday.

At the top of the index was Entain, up 4.1%. Jefferies raised the stock to 'buy' from 'hold'.

On the other hand, Fresnillo closed down 5.2%. Morgan Stanley cut the miner's stock to 'underweight' from 'equal-weight'. Housebuilders Berkeley Group and Barratt Developments were also stung by a broker downgrade, falling 3.4% and 2.5% respectively after UBS cut the stocks to 'neutral' from 'buy'.

In the FTSE 250 index, IP Group jumped 5.9%.

The investors launched a share buyback worth up to GBP20 million. The programme will run until the end of 2024.

"The board remains committed to making regular cash returns to shareholders from realisations," IP Group said.

On London's AIM, N4 Pharma surged 39%.

The pharmaceutical company announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Chief Executive Officer Nigel Theobald said: "This continued success shows that Nuvec has the potential to be successfully used as an oral delivery system with many potential applications such as a vaccine, a product for irritable bowel disease or to treat colonic cancer among many possible examples. Given the complexities involved in oral delivery this early success with Nuvec represents a potentially massive opportunity and point of difference for Nuvec and its use as delivery system to target multiple diseases."

Cap-XX plummeted 57%, after it responded to a court decision regarding its patent infringement case against Maxwell Technologies.

The Sydney-based company, which manufactures supercapacitors for portable electronic devices, started its patent infringement trial against Maxwell Technologies last Monday.

The complaint, filed in September 2019, alleged that Maxwell Technologies had directly and indirectly infringed on Cap-XX's patents for several capacitor products.

On Friday, the jury in the Delaware district court affirmed that Cap-XX's patents were invalid, thereby nullifying the accusations against Maxwell. As a result, Maxwell is not liable to pay any damages or license fees.

Gold was quoted at USD2,022.88 an ounce at the London equities close Monday, lower against USD2,034.62 at the close on Friday.

In Tuesday's UK corporate calendar, there is a consumer price index for the eurozone at 1000 GMT.

The economic calendar for has half year results from Hipgnosis Songs Fund. There is a trading statement from Nanoco.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
9 Mar 2023 14:32

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Nov 2022 11:16

AIM WINNERS & LOSERS: Parsley Box to exit AIM as shares wilt since IPO

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
18 Nov 2022 11:02

N4 Pharma plummets on broker offer to raise up to GBP1 million

(Alliance News) - N4 Pharma PLC shares plummeted on Friday, after it raised GBP1.0 million through a placing of 50.0 million shares and announced a broker offer to raise up to GBP1.0 million.

Read more
18 Nov 2022 08:11

N4 Pharma shares tumble following placing, broker offer announcement

(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer aimed at raising as much as another £1.0m.

Read more
1 Nov 2022 17:06

IN BRIEF: N4 Pharma expands patent application claims for Nuvec

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Provides a patent application update for Nuvec.

Read more
4 Oct 2022 13:32

N4 Pharma reports success in recent 'Nuvec' testing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA (siRNA) probes.

Read more
4 Oct 2022 11:19

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
4 Oct 2022 10:38

N4 Pharma announces successful test in next stage of Nuvec development

(Alliance News) - N4 Pharma PLC on Tuesday announced successful in vitro testing of Nuvec when loaded with two small interfering siRNA probes.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
29 Sep 2022 15:09

EARNINGS UPDATES: Crestchic raises outlook on record year-to-date

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Sep 2022 12:11

N4 Pharma reduces losses as Nuvec development continues

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reduced its operating loss in the first half, it reported on Thursday, to £0.75m from £0.97m a year earlier.

Read more
14 Sep 2022 12:03

IN BRIEF: N4 completes testing on loading Nuvec drug with siRNA probes

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Completes initial testing on loading its Nuvec treatment with two generic siRNA probes at the same time. siRNA can prevent cells from communicating, potentially preventing cancer cells from replicating. N4 are now undertaking experiments using siRNA sequences against known oncology targets. This includes in vitro using a lung cancer cell line and, after that, in vivo studies in mice. Chief Executive Officer Nigel Theobald said: "We have now identified a very strong commercial point of difference for Nuvec in that it can be successfully loaded with at least two siRNA genes".

Read more
15 Jul 2022 21:26

TRADING UPDATES: Premier Miton assets dip; Challenger Energy CFO quits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
15 Jul 2022 13:23

N4 Pharma upbeat on latest tumour suppression study data

(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.